Idorsia starts late-stage trial of heart attack drug

ZURICH (Reuters) – Idorsia is launching a late-stage trial to evaluate the efficacy and safety of its experimental drug selatogrel in treating suspected acute myocardial infarction (AMI), the Swiss drugmaker said on Monday. Besides aspirin, there are no treatment options available for the critical time from onset of AMI, or heart attack, symptoms to first medical contact, it said. Upon […]
Continue reading »